What are the key takeaways from this The RTW Podcast episode?

Key insights include: **Ultra-Rapid Treatment Response:** GH001 delivers measurable improvement in depressive symptoms within two hours of administration, with patients reporting ability to manage daily tasks and enjoy activities the same day. This contrasts sharply with traditional oral antidepressants requiring four to six weeks to show effect and SPRAVATO's complex eight-week induction requiring twice-weekly then weekly dosing before benefits appear.; **Superior Clinical Outcomes:** Phase 2b data demonstrated 15.5-point placebo-adjusted reduction on MADRS scale with 57.5% remission rate at day eight, compared to SPRAVATO monotherapy achieving 21% remission at day 28. The treatment requires average of four clinic visits over six months, with 97.4% of patients discharge-ready within one hour after final dose, showing no sedation or dissociation at discharge.; **Simplified Treatment Protocol:** GH001 administration involves one to three inhalations during a one to three-hour clinic visit, without mandated psychotherapy sessions. This approach reduces cost, improves scalability, and provides patient choice compared to psychotherapy-integrated protocols. Side effects remain mild to moderate, occurring primarily during the psychoactive phase, eliminating next-day drowsiness and driving restrictions associated with competing treatments.

What did Ditching Delay discuss on The RTW Podcast?

GH Research CEO Vili Valcheva discusses GH001 (mebifotidine), a synthetic five-methoxy-DMT therapy for treatment-resistant depression that shows 57.5% remission rates at day eight versus SPRAVATO's 21% at day 28, with same-day symptom improvement and infrequent dosing averaging four treatments per six months. Key topics include: **Ultra-Rapid Treatment Response:** GH001 delivers measurable improvement in depressive symptoms within two hours of administration, with patients reporting ability to manage daily tasks and enjoy activities the same day. This contrasts sharply with traditional oral antidepressants requiring four to six weeks to show effect and SPRAVATO's complex eight-week induction requiring twice-weekly then weekly dosing before benefits appear.; **Superior Clinical Outcomes:** Phase 2b data demonstrated 15.5-point placebo-adjusted reduction on MADRS scale with 57.5% remission rate at day eight, compared to SPRAVATO monotherapy achieving 21% remission at day 28. The treatment requires average of four clinic visits over six months, with 97.4% of patients discharge-ready within one hour after final dose, showing no sedation or dissociation at discharge..

How long is this episode of The RTW Podcast?

This episode is 22 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The RTW Podcast

Ditching Delay: GH001’s Instant Impact on Depression

May 5, 2025

22 min episode · 2 min read

Ditching Delay

Episode

22 min

Read time

2 min

Topics

Health & Wellness, Leadership, Psychology & Behavior

AI-Generated Summary

Published Feb 12, 2026

Key Takeaways

✓Ultra-Rapid Treatment Response: GH001 delivers measurable improvement in depressive symptoms within two hours of administration, with patients reporting ability to manage daily tasks and enjoy activities the same day. This contrasts sharply with traditional oral antidepressants requiring four to six weeks to show effect and SPRAVATO's complex eight-week induction requiring twice-weekly then weekly dosing before benefits appear.
✓Superior Clinical Outcomes: Phase 2b data demonstrated 15.5-point placebo-adjusted reduction on MADRS scale with 57.5% remission rate at day eight, compared to SPRAVATO monotherapy achieving 21% remission at day 28. The treatment requires average of four clinic visits over six months, with 97.4% of patients discharge-ready within one hour after final dose, showing no sedation or dissociation at discharge.
✓Simplified Treatment Protocol: GH001 administration involves one to three inhalations during a one to three-hour clinic visit, without mandated psychotherapy sessions. This approach reduces cost, improves scalability, and provides patient choice compared to psychotherapy-integrated protocols. Side effects remain mild to moderate, occurring primarily during the psychoactive phase, eliminating next-day drowsiness and driving restrictions associated with competing treatments.
✓Scheduled Substance Development Challenges: Developing five-methoxy-DMT requires obtaining separate controlled drug licenses for each trial site and each new trial, with regulations varying by state. Planning timelines must account for manufacturing, distribution, and on-site storage rules. GH Research's completion of 80-patient trial across 20-plus sites established operational know-how for managing these regulatory complexities in future pivotal programs.
✓Expansion Potential Beyond TRD: Proof-of-concept data exists for postpartum depression and bipolar disorder type two, with phase 2b showing effectiveness for anxiety symptoms. Scientific community identifies additional applications including PTSD, terminal cancer patients, and chronic pain conditions. The treatment's rapid-acting mechanism and infrequent dosing model positions it for multiple mental health indications once treatment-resistant depression approval establishes the platform.

What It Covers

GH Research CEO Vili Valcheva discusses GH001 (mebifotidine), a synthetic five-methoxy-DMT therapy for treatment-resistant depression that shows 57.5% remission rates at day eight versus SPRAVATO's 21% at day 28, with same-day symptom improvement and infrequent dosing averaging four treatments per six months.

Key Questions Answered

•Ultra-Rapid Treatment Response: GH001 delivers measurable improvement in depressive symptoms within two hours of administration, with patients reporting ability to manage daily tasks and enjoy activities the same day. This contrasts sharply with traditional oral antidepressants requiring four to six weeks to show effect and SPRAVATO's complex eight-week induction requiring twice-weekly then weekly dosing before benefits appear.
•Superior Clinical Outcomes: Phase 2b data demonstrated 15.5-point placebo-adjusted reduction on MADRS scale with 57.5% remission rate at day eight, compared to SPRAVATO monotherapy achieving 21% remission at day 28. The treatment requires average of four clinic visits over six months, with 97.4% of patients discharge-ready within one hour after final dose, showing no sedation or dissociation at discharge.
•Simplified Treatment Protocol: GH001 administration involves one to three inhalations during a one to three-hour clinic visit, without mandated psychotherapy sessions. This approach reduces cost, improves scalability, and provides patient choice compared to psychotherapy-integrated protocols. Side effects remain mild to moderate, occurring primarily during the psychoactive phase, eliminating next-day drowsiness and driving restrictions associated with competing treatments.
•Scheduled Substance Development Challenges: Developing five-methoxy-DMT requires obtaining separate controlled drug licenses for each trial site and each new trial, with regulations varying by state. Planning timelines must account for manufacturing, distribution, and on-site storage rules. GH Research's completion of 80-patient trial across 20-plus sites established operational know-how for managing these regulatory complexities in future pivotal programs.
•Expansion Potential Beyond TRD: Proof-of-concept data exists for postpartum depression and bipolar disorder type two, with phase 2b showing effectiveness for anxiety symptoms. Scientific community identifies additional applications including PTSD, terminal cancer patients, and chronic pain conditions. The treatment's rapid-acting mechanism and infrequent dosing model positions it for multiple mental health indications once treatment-resistant depression approval establishes the platform.

Notable Moment

When the phase 2b data revealed a 15.5-point MADRS delta, internal team members who had predicted seven to ten points were stunned by results exceeding expectations by over 50%. The magnitude prompted key opinion leaders to proactively write papers and guidance on managing functional unblinding to support FDA discussions.

Know someone who'd find this useful?

Episode Transcript

When you have to refer to the compound, has meb Mebifotidine. Mebifotidine taken over yet, or is it still five methoxy DMT? We refer to it as GHO one or mebifotidine. Welcome to the RTW podcast. I'm today's host, Connor Williams, senior research analyst at RTW, responsible for research in neurological disease. Today, I'm speaking with esteemed industry colleague, doctor Vily Valcheva, CEO of GH Research, a cutting edge biotech company advancing therapies for psychiatric and neurological disorders. You wouldn't normally find me in RTW's podcast studio, but there's quite a bit going on in neuropsych that's worth talking about. I recently had a conversation with our chief business officer, Stephanie Sirota, about the emergence of psychedelics as a transformative therapy for treatment resistant depression. And now I have the privilege of speaking to doctor Valcheva, an industry leader with more than twenty years of leadership experience in the pharmaceutical and biotech industries, including companies such as Albireo, Ipsen, and Sanofi. Vili, thank you for joining us today. Great to be here, Conor. I'm really excited about this. Let's begin with GH Research. What is GH Research, and what's the main problem you're trying to solve? GH Research is a biotech company. We are headquartered in Dublin, Ireland. We are developing a treatment for mental diseases, and our value proposition is that it would be a practice changing treatment that would lead to ultra rapid remission, which can be sustained within frequent administrations. Patients with depression nowadays suffer insurmountably. They have years of depressive symptoms without any treatments that could lead to remission. Usually, it takes oral antidepressants four to six weeks to work, and there's very low percentage of patients that get any remission. We're developing a new treatment, g h zero zero one, that could lead to improvement in the depressive symptoms even on the same day of the treatment, and then it's sustained months and months with infrequent administrations. I know you said you're treating depression, but it's specifically treatment resistant depression. What's the difference between that and maybe run of the mill depression that you might first treat with an SSRI? So patients with treatment resistant depression would have multiple major depressive episodes. They would be treated with at least two prior treatments that would have been taken in the appropriate dose and would be ineffective for weeks. These patients, with time, become resistant to any anti depressive treatments, and it's hard to find a new treatment. So they could suffer for years before anything works. So that's the treatment resistant depression. There's a high unmet need, and believe it or not, there's millions of patients out there in need of new treatment. Right. Three million patients in The US with treatment resistant depression. Yeah. Correct. I know standard of care's SPRAVATO. How do you think about SPRAVATO, particularly as it compares to your therapy that you're developing? Yeah. SPRAVATO is currently the benchmark. It gained approval a few years ago. The difference between SPRAVATO and …

Get the full transcript (3,719 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The RTW Podcast transcripts →